Pacira BioSciences, Inc. reported $180 million in sales, up 2.25% from the year earlier period for the June quarter. Unfortunately, the company’s operating profit plunged 70% on those sales.
Tough Quarter for Pacira BioSciences
2 min read Premium comments
Pacira BioSciencessecond quarter 2025 earnings
| Pacira BioSciences, Inc. 2025 Report ($000s): Months Ended 06/30/25 | ||||||
| 3 Month Sales | 6 Month Sales | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $176,387 | $180,347 | 2.25% | $342,211 | $347,941 | 1.67% | |
| Op Profit | Op Profit | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $28,240 | $8,499 | -69.90% | $41,452 | $10,489 | -74.70% | |
| 16.01% | 4.71% | 12.11% | 3.01% | |||
| EPS | EPS | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $0.39 | -$0.11 | -128.21% | $0.58 | $0.00 | -100.00% | |
| 2026 Sales Estimate | 2025 Sales Estimate | |||||
| Consensus | Change | Consensus | Change | |||
| $785,000 | 4.33% | $751,660 | 6.65% | |||
Source: RRY Publications LLC
Pacira’s Q2: Growth on Paper, Pain in the Margins
Pacira BioSciences walked into its Q2 2025 earnings call with a classic orthopedic business paradox: sales creeping upward, profits collapsing downward.
Revenue came in at $180 million, a modest 2.25% year-over-year gain. But operating profit? It fell off a cliff—down 70%.
That didn’t stop CEO Frank Lee from dressing the wound with upbeat language, assuring analysts that the company delivered “solid execution” and is on track with its “5×30 path to growth and value creation.”
Translation: Pacira is leaning on two pillars — commercial growth (mainly EXPAREL) and pipeline bets (such as PCRX-201).
The Good News
- EXPAREL: Despite a softening surgical volume environment, Pacira reported encouraging traction in outpatient settings — particularly hospital outpatient departments (HOPDs) and ambulatory surgery centers (ASCs). A new Centers for Medicare and Medicaid Services (CMS) policy starting in 2026, which phases out the inpatient-only list and shifts hundreds of procedures into ASC coverage, could expand EXPAREL’s playing field dramatically.
- Debt reduction: The balance sheet looks healthier, always a welcome sign for investors.
- ZILRETTA partnership: Teaming up with Johnson & Johnson MedTech gives ZILRETTA broader reach. Doubling the sales force overnight, courtesy of J&J, is no small advantage in the osteoarthritis (OA) pain space.
The Not-So-Good News
- Margins are under pressure. Growing sales while profits evaporate is never a sustainable story for Wall Street.
- Surgical volumes are flat-to-down. Outpatient volumes dipped slightly versus last year; inpatient stayed flat. Pacira’s growth in ASCs is encouraging — but it’s happening against a sluggish backdrop.
- Pipeline risk. EXPAREL remains the anchor, but true upside depends on delivering pipeline assets like PCRX-201. Until then, Pacira lives and dies by its flagship franchise.
Analyst Pressure
Needham’s John Gionco pressed leadership on surgical volume dynamics and growth strategy. CCO Brendan Teehan’s response emphasized:
- Targeting regional payer plans for alignment with surgical opportunities.
- Building reimbursement wins outside the bundle through NOPAIN initiatives.
- Staying “opportunistic” in capturing volume where possible.
Encouraging? Yes. Sufficient to offset collapsing margins? That’s less clear.
Executive Take-Home
For analysts and investors watching Pacira, the quarter underscores three key themes:
- Outpatient is the battleground. CMS’s 2026 move to phase out the inpatient-only list could supercharge EXPAREL adoption in ASCs and HOPDs. Every orthopedic company should be modeling for this shift.
- Partnerships matter. The J&J MedTech collaboration instantly scales ZILRETTA’s reach — an instructive play for mid-cap companies trying to punch above their salesforce weight.
- Margins tell the truth. Sales growth is nice, but operating profit tells the real health story. Pacira has yet to show how its strategic moves translate into bottom-line recovery.
Pacira’s Q2 was less about results and more about promises. For investors, the lesson is clear: the shift to outpatient orthopedics is real, partnerships can turbocharge distribution, but profit discipline remains the toughest operation of all.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.